Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323101 · ClinicalTrials.gov registry record · Phase 4
Doxycycline Effects on Inflammation in Cystic Fibrosis
A Phase 4 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT01323101 is a Phase 4 study that has completed, run by University of Southern California. The registered enrollment target is 21 participants.
The verdict
NCT01323101, a Phase 4 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Doxycycline is known to exhibit immune modulatory activities beyond its antibacterial effects. In particular, doxycycline is a potent inhibitor of matrix metalloproteinase 9, which is a protease derived largely from neutrophils. Recent studies demonstrate a significant correlation between pulmonary disease severity and sputum concentrations of MMP-9 in patients with CF. In addition, sputum MMP-9 levels are associated with airway remodeling in CF. The goal of this study is to determine the therapeutic potential of doxycycline in modulating host airway inflammation in patients with CF. Specifically, the study will characterize the PK /PD of doxycycline, evaluate the safety of short term therapy, and explore the concentration effect relationship between doxycycline exposure and sputum biomarker levels.
Interventions
- DRUG Doxycycline
- OTHER No doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323101
The ClinicalTrials.gov registry entry for NCT01323101 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxycycline is the first listed.
NCT01323101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01323101 about?
NCT01323101 is a clinical study titled "Doxycycline Effects on Inflammation in Cystic Fibrosis". Doxycycline is known to exhibit immune modulatory activities beyond its antibacterial effects. In particular, doxycycline is a potent inhibitor of matrix metalloproteinase 9, which is a protease derived largely from neutrophils. Recent studies demonstrate a significant correlation between pulmonary ...
What is the current status of trial NCT01323101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2008-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01323101?
The interventions under investigation include: Doxycycline (DRUG), No doxycycline (OTHER).
Who is sponsoring clinical trial NCT01323101?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.